Show Summary Details
Page of

Malignant lymphomas 

Malignant lymphomas
Malignant lymphomas

Frank Kroschinsky

, Friedrich Stölzel

, Stefano A. Pileri

, Björn Chapuy

, Rainer Ordemann

, Christian Gisselbrecht

, Tim Illidge

, David C. Hodgson

, Mary K. Gospodarowicz

, Christina Schütze

, and Gerald Wulf

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 July 2021

Malignant lymphomas represent neoplasias arising from the peripheral lymphatic tissues in lymph nodes and extranodal sites. Classification in Hodgkin’s (HL) and non-Hodgkin’s lymphomas (NHL), B- or T-cell origin, nodal or extranodal involvement, and indolent or aggressive diseases gives a basic algorithm for clinical management. The introduction of positron emission tomography (PET) using 18F-Fluoro-deoxyglucose (18F-FDG) both alone or in combination with CT or MRI (PET/CT) improved accuracy of staging procedures and increasingly influence treatment algorithms. Current treatment options include classic cytotoxic drugs and radiotherapy and have been expanded by monoclonal antibodies, agents targeting signalling pathways and transplant procedures during the last two decades. Using this arsenal about 90% of patients with Hodgkin’s lymphomas and 60–80% of patients with aggressive B-NHL can be cured today.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.